Pembrolizumab (MK 3475) With or Without Talimogene Laherparepvec or placebo in in Unresectable Melanoma

• Register: EUCTR
• Last refreshed on: 5 April 2021
• Main ID: EUCTR2014-000185-22-GR
• Date of registration: 06/08/2015
• Prospective Registration: Yes
• Primary sponsor: Amgen Inc.
• Public title: Pembrolizumab (MK 3475) With or Without Talimogene Laherparepvec or placebo in in Unresectable Melanoma
• Scientific title: A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable, Stage IIIB to IVM1c Melanoma (MASTERKEY-265)
• Date of first enrolment: 12/11/2015
• Target sample size: 680
• Recruitment status: Not Recruiting
• URL: https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-000185-22
• Study type: Interventional clinical trial of medicinal product
• Study design: Controlled: no; Randomised: no; Open: no; Single blind: no; Double blind: yes; Parallel group: no; Cross over: no; Other: no; If controlled, specify comparator, Other Medicinial Product: no; Placebo: yes; Other: yes; Other specify the comparator: Keytruda
• Phase: Human pharmacology (Phase I): yes Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): yes Therapeutic use (Phase IV): no

Countries of recruitment

Australia, Austria, Belgium, Canada, Czech Republic, Finland, France, Germany, Greece, Hungary, Italy, Netherlands, Norway, Poland, Portugal, Russian Federation, South Africa, Spain, Sweden, Switzerland, United States

Contacts

• Name: Medical Information
• Affiliation: Amgen Hellas ?.?.?

• Name: Medical Information
• Affiliation: Amgen Hellas ?.?.?

Key inclusion & exclusion criteria

Inclusion criteria:
Phase 1b and Phase 3:
• Male or female age = 18 years with histologically confirmed diagnosis
of melanoma and stage IIIB to IVM1c for whom surgery in not
recommended.
• Subjects must have measurable disease and be a candidate for
intralesional therapy administration into cutaneous, subcutaneous, or
nodal lesions.
• Subjects must have Eastern Cooperative Oncology Group (ECOG)
performance status of 0 or 1, and adequate hematologic, hepatic, renal,
and coagulation function.
Phase 1b only:
• Subjects enrolled in phase 1b must be treatment naïve (i.e., must not
have received any prior systemic anticancer treatment consisting of
chemotherapy, immunotherapy, or targeted therapy) given in a nonadjuvant
setting for unresectable stage IIIB to IVM1c melanoma.
• Subjects who received prior adjuvant therapy for melanoma will not be
excluded (including, but not limited to, radiotherapy, interferon, limb
infusion/perfusion, or use of investigational agents in the adjuvant
setting) with the exception that prior adjuvant therapy with inhibitors of
programmed cell death 1 (PD-1) or programmed cell death ligand 1 (PDL1)
is not allowed. However, if the subject received adjuvant therapy,
the
subject must have completed therapy at least 3 months prior to
enrolment.
Phase 3 only:
• Subjects enrolled in phase 3 with serine/threonine protein kinase B-Raf V600 BRAFV600 wild-type tumors must
not have received any prior systemic anticancer treatment consisting of
chemotherapy, immunotherapy, or targeted therapy given in a nonadjuvant
setting for unresectable stage IIIB to IVM1c melanoma.
• Subjects enrolled in phase 3 with serine/threonine protein kinase BRaf
V600 (BRAFV600) mutated tumors who have received prior BRAF
inhibitor therapy either alone or in combination with MEK inhibitor as
their only prior systemic therapy are eligible for the phase 3 of this
study. Subjects with BRAFV600
mutant melanoma or unknown BRAFV600 mutation status who have not
received a BRAF inhibitor are also eligible for the phase 3 of this study as
first-line treatment if they meet the following criteria: lactate
dehydrogenase (LDH) < upper limit of normal (ULN), no clinically
significant tumor related symptoms, and absence of rapidly progressing
metastatic melanoma. Subjects (BRAF mutant, wildtype and UNK) who received prior adjuvant therapy for
melanoma will not be excluded (including, but not limited to, interferon,
ipilimumab, limb infusion/perfusion, or use of investigational agents in
the adjuvant setting) with the exception that prior adjuvant therapy with
inhibitors of PD-1 OR PD-L1 is not allowed. However, if the subject
received adjuvant therapy, the subject must have completed therapy at
least 28 days prior to enrolment.
• Subjects must have a tumor sample (archival sample or newly
obtained biopsy) that is adequate for PD-L1 assessment prior to
randomization.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 330
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 350

Exclusion criteria:
Phase 1b and Phase 3:
• Subjects must not have clinically active cerebral metastases and/or
carcinomatous meningitis.
• Subjects with up to 3 cerebral metastases may be enrolled, provided
that all lesions have been adequately treated with stereotactic radiation
therapy, craniotomy, or Gamma Knife therapy, with no evidence of
progression, and not requiring steroids, for at least 2 months prior
to enrolment. Carcinomatous meningitis is excluded regardless of clinical
stability.
• Subjects must not have primary uveal or mucosal melanoma, history or
evidence of melanoma associated with immunodeficiency states (e.g.,
hereditary immune deficiency, organ transplant, or leukemia), or history
of other malignancy within the past 3 years with the exceptions of the
prior malignancies noted in Section 4.1.2.
• Subjects may not have been previously treated with talimogene
laherparepvec, any other oncolytic virus, pembrolizumab, or any other
inhibitor of PD-1, PD-L1, or programmed cell death ligand 2 (PD-L2).
Prior treatment with other immunotherapies ( e.g., anti-CD137, or
cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) inhibitor, or any
other antibody or drug specifically targeting T-cell co-stimulation or
checkpoint pathways), is allowed only in the adjuvant setting.
• Subjects must not have history or evidence of symptomatic
autoimmune glomerulonephritis, vasculitis, other symptomatic
autoimmune disease, documented history of autoimmune disease or
syndrome requiring systemic treatment in the past 2 years (ie, with use
of disease modifying agents, steroids or immunosuppressive agents)
except vitiligo or resolved childhood asthma/atopy, or evidence of
clinically significant immunosuppression.
• Subjects must not have active herpetic skin lesions or prior
complications of herpetic infection (eg, herpetic keratitis or encephalitis)
and must not require intermittent or chronic treatment with an
antiherpetic drug (eg, acyclovir), other than intermittent topical use.


Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes

Health Condition(s) or Problem(s) studied

Therapeutic area: Diseases [C] - Cancer [C04]

Unresectable Stage IIIB to IVM1c Melanoma
MedDRA version: 21.1 Level: LLT Classification code 10053571 Term: Melanoma System Organ Class: 100000004864

Intervention(s)

Trade Name: IMLYGIC
Product Name: Talimogene Laherparepvec
Product Code: AMG 678
Pharmaceutical Form: Solution for injection
INN or Proposed INN: Talimogene laherparepvec
Current Sponsor code: AMG 678
Other descriptive name: TALIMOGENE LAHERPAREPVEC
Concentration unit: PFU/ml plaque forming unit(s)/millilitre
Concentration type: equal
Concentration number: 10e6-
Pharmaceutical form of the placebo: Solution for injection
Route of administration of the placebo: Intralesional use

Trade Name: IMLYGIC
Product Name: Talimogene Laherparepvec
Product Code: AMG 678
Pharmaceutical Form: Solution for injection
INN or Proposed INN: Talimogene laherparepvec
Current Sponsor code: AMG 678
Other descriptive name: TALIMOGENE LAHERPAREPVEC
Concentration unit: PFU/ml plaque forming unit(s)/millilitre
Concentration type: equal
Concentration number: 10e8-
Pharmaceutical form of the placebo: Solution for injection
Route of administration of the placebo: Intralesional use

Trade Name: Keytruda
Product Code: MK-3475
Pharmaceutical Form: Solution for infusion
INN or Proposed INN: Pembrolizumab
CAS Number: 1374853-91-4
Current Sponsor code: MK-3475
Other descriptive name: MK-3475
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 200-

Primary Outcome(s)

Main Objective: Phase 1b: To evaluate the safety, as assessed by incidence of dose limiting toxicity (DLT), of talimogene laherparepvec in combination with pembrolizumab in subjects with previously untreated, unresectable, stage IIIB to IVM1c melanoma.

Phase 3: To evaluate the efficacy of talimogene laherparepvec with
pembrolizumab versus placebo with pembrolizumab, as assessed by
progression-free survival (PFS) (response evaluation by blinded
independent central review using modified Response Evaluation Criteria in Solid Tumors 1.1 [RECIST]) and overall survival (OS).

Timepoint(s) of evaluation of this end point: Primary Completion: The time when the last subject is assessed or receives an intervention for the purposes of final collection of data for the primary analysis of phase 3. The timing of the primary analyses for the primary endpoint(s), for the purpose of conducting the primary analysis, whether the study concluded as planned in the protocol or was terminated early.
End of Trial: The date when the last subject across all sites is assessed or receives an intervention for evaluation in the study (ie, last subject last visit), following any additional parts in the study (eg, long-term follow-up), as applicable.

Primary end point(s): Phase 1b:
• Incidence of DLT
Phase 3:
• PFS (response evaluation by blinded independent central review
assessed using modified RECIST 1.1) (PFS1) and OS

Secondary Objective: Please refer to the corresponding field of the protocol as the space is insufficient

Secondary Outcome(s)

Secondary end point(s): Phase 1b:
• Confirmed ORR (CR+PR) (response evaluation by investigator using modified irRC).
• BOR, DRR (CR or PR for duration of 6 months or longer), DOR (the time from date of the initial confirmed response to the date of the first documented PD or death; a single, unconfirmed PD at the last assessment will also be considered for the end of DOR), DCR, and PFS (response evaluation by investigator using modified irRC).
• OS.
• Incidence of treatment-emergent and treatment-related adverse events (all AEs, grade = 3 AEs, SAEs, fatal AEs, and AEs defined as events of interest).
Phase 3:
• iCRR by blinded independent central review using modified irRC-RECIST
•iPFS by blinded independent central review using modified irRC-RECIST (PFS2)
• OS in subjects excluding stage IVM1c per CRF
• ORR (CR+PR), BOR, DRR, DOR, and DCR (response evaluation by blinded independent central review assessed using modified RECIST 1.1 and iORR (iCR + iPR), iBOR, iDRR, iDOR, and iDCR (response evaluation by blinded independent central review assessedusing modified irRC-RECIST)
• Incidence of treatment-emergent and treatment-related AEs (all AEs, grade = 3 AEs, serious adverse events, fatal AEs, and AEs defined as events of interest), and abnormal laboratory tests
• Changes in EORTC QLQ-C30 GHS/QoL subscale

Timepoint(s) of evaluation of this end point: The clinical study report (CSR) will be written based on the results from
the OS primary analysis for phase 3, which will also include safety data
from subjects in phase 1b. However, a CSR will be prepared should there
be a decision for unblinding the study team based on early stopping for
safety, efficacy, or futility (Section 10.4.1). Amgen senior management
will make the decision to unblind the study team based on the DMC's
recommendations; however, only a subset of the study team will be
unblinded prior to the OS primary analysis.

Secondary ID(s)

NCT02263508

20110265

2014-000185-22-SE

Source(s) of Monetary Support

Amgen Inc.

Merck Sharp and Dohme International GmbH

Ethics review

Status: Approved
Approval date: 07/10/2015
Contact: